|Bid||0.00 x 0|
|Ask||120.00 x 0|
|Day's Range||100.00 - 100.00|
|52 Week Range||100.00 - 111.65|
|PE Ratio (TTM)||96.81|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.
Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer. The trial, which was testing the drug as a second-line treatment, also failed to prevent the cancer from progressing in patients whose tumors expressed the PD-LI protein, the company said. The U.S. regulator earlier this year approved Keytruda as a third-line treatment for gastric cancer patients, who showed no response to two or more prior lines of therapy.
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.
Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.
Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.
Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...
Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International
After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday.
Wall Street analysts estimate Merck & Co.’s (MRK) top line to rise 1.1% to ~$40.2 billion in 2017. EPS (earnings per share) is expected to be $3.94 for 2017.
Pepsi is a fantastic business with a healthy dividend. But your quarterly check will be even larger if you invest in these three companies.
In 3Q17, Merck's Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
The combined revenues of Merck's (MRK) Januvia and Janumet in 3Q17 was $1.52 billion, a 2% decline compared to $1.55 billion in 3Q16, mainly due to lower sales of Janumet.
LONDON/FRANKFURT (Reuters) - Swiss food giant Nestle (NESN.S) and the private equity owners of German drug firm Stada (STAGn.DE) are both preparing tentative bids for Merck KgaA's (MRCG.DE) consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros (£3.5 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.
Merck & Co.'s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.